Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance

To the Editor： Nivolumab, an antibody that blocks the immune-checkpoint inhibitor programmed cell death protein 1 （PD-1）, has recently shown some promising results in clinical trials for all nonsmall cell lung cancer subtypes It is required that clinic practice about anti-PD-I antibodies provided real data never observed in previously known clinical trials. In addition, It is also needed to assess the role ofnivolumab in tile subsequent therapy oftyrosine kinase inhibitor （TKI） acquired resistance.